P. Elvin

发表

Regional copy number–independent deregulation of transcription in cancer

D. Pinkel, D. Albertson, Nicolas Stransky, 2006, Nature Genetics.

Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes--a study of 130 invasive ductal breast carcinomas.

Nicolas Stransky, J. Thiery, A. Vincent-Salomon, 2005, Cancer research.

Estimated Costs of False Laboratory Diagnoses of Tuberculosis in Three Patients

E. Nardell, P. Elvin, C. Braden, 2002, Emerging infectious diseases.

Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer

P. Elvin, S. Kopetz, M. Overman, 2014, BMC Cancer.

Gene Array and Fluorescence In situ Hybridization Biomarkers of Activity of Saracatinib (AZD0530), a Src Inhibitor, in a Preclinical Model of Colorectal Cancer

M. Varella‐Garcia, P. Elvin, D. Gao, 2010, Clinical Cancer Research.

Adaptation of the Boyden chamber to flow conditions: rheological effects on chemotaxis.

P. Elvin, C. Evans, B. Drake, 1983, Journal of immunological methods.

Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function.

Jason V. Evans, S. Weed, P. Elvin, 2009, Journal of cancer science & therapy.

A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies

R. Herbst, P. Elvin, A. Platt, 2015, BMC Cancer.

Cell adhesion and experimental metastasis: a study using the B16 malignant melanoma model system.

P. Elvin, C. Evans, 1984, European journal of cancer & clinical oncology.

Nonclinical Selection Criteria for Maximizing Yield of Nucleic Acid Amplification Tests in Tuberculosis Diagnosis

P. Elvin, J. Bernardo, Linda L. Han, 2012, Journal of Clinical Microbiology.

Induction of apoptosis by anti-cancer drugs with disparate modes of action: kinetics of cell death and changes in c-myc expression.

P. Elvin, J. Hickman, A. Wood, 1995, British Journal of Cancer.

Rectal cancer: evaluation of staging with endosonography.

P. Elvin, W. Kraaz, B. Glimelius, 1997, Radiology.

Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer.

M. Duffy, E. McDermott, N. O’higgins, 1996, Enzyme & protein.

Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response

P. Elvin, M. O’Connor, S. Im, 2018, Molecular Cancer Therapeutics.

Src inhibitors in early breast cancer: a methodology, feasibility and variability study

P. Elvin, J. Dixon, C. Womack, 2009, Breast Cancer Research and Treatment.

Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors

J. Baselga, I. Chirivella, J. Tabernero, 2010, Clinical Cancer Research.

Chemical Therapeutics Discovery & Preclinical Development Antitumor Activity of Saracatinib ( AZD 0530 ) , a cSrc / Abl Kinase Inhibitor , Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer

Y. Bang, P. Elvin, S. Im, 2013 .

Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer

Y. Bang, P. Elvin, S. Im, 2012, Molecular Cancer Therapeutics.

Can Pha Act

I. Chirivella, J. Tabernero, P. Elvin, 2010 .

False-negative MRI biomarkers of tumour response to targeted cancer therapeutics

J. Waterton, A. Ryan, P. Elvin, 2012, British Journal of Cancer.

The adhesiveness of normal and SV40-transformed BALB/c 3T3 cells: effects of culture density and shear rate.

P. Elvin, C. Evans, 1982, European journal of cancer & clinical oncology.

Vascular endothelial growth factor stimulates protein kinase C-dependent phospholipase D activity in endothelial cells.

D. Kerr, P. Elvin, A. Martín, 1996, Laboratory investigation; a journal of technical methods and pathology.

The effects of the B16 malignant melanoma on induced inflammatory responses in host mice: inhibition of macrophage exudation.

P. Elvin, C. Evans, W. D'Arrigo, 1985, Cancer letters.

of Normal and BALB/c 3T3 Cells: Density

P. Elvin, C. Evans, 1982 .

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

J. Barrett, J. Schellens, P. Elvin, 2017, Clinical Cancer Research.

Abstract LB-66: Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors .

M. Ranson, J. Schellens, K. Tamura, 2013 .

Results of two Phase 1 multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors.

M. Ranson, J. Schellens, K. Tamura, 2013 .

Tumour invasion and metastasis: challenges facing drug discovery.

P. Elvin, A. Garner, 2005, Current opinion in pharmacology.

Inhibition of Src Impairs the Growth of Met-Addicted Gastric Tumors

P. Elvin, L. Trusolino, A. Bertotti, 2010, Clinical Cancer Research.

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

N. Carragher, P. Elvin, B. Davies, 2009, Molecular oncology.

Plasminogen activator inhibitor type 2 in breast cancer.

M. Duffy, E. McDermott, N. O’higgins, 1997, British Journal of Cancer.

Inhibition of human bladder tumour cell growth by fibroblast growth factor receptor 2b is independent of its kinase activity. Involvement of the carboxy-terminal region of the receptor

J. Thiery, F. Radvanyi, I. Bernard-Pierrot, 2004, Oncogene.

Pharmacodynamic activity of the AKT inhibitor AZD5363 in patients with advanced solid tumors.

J. Barrett, K. Tamura, P. Elvin, 2014 .

Anti-tumour activity of novel adducts of ascorbic acid with aldehydes.

P. Elvin, T. Slater, 1981, European Journal of Cancer and Clinical Oncology.

Cell adhesiveness and the cell cycle: correlation in synchronized Balb/c 3T3 cells

P. Elvin, C. Evans, 1983, Biology of the cell.

Amplification and sequencing of genomic breakpoints located within the M-bcr region by Vectorette-mediated polymerase chain reaction.

P. Elvin, K. Mills, A. Burnett, 1992, Leukemia.

Isolation of cDNA clones using yeast artificial chromosome probes

Alexander F. Markham, D. Black, R. Anand, 1990, Nucleic Acids Res..

Abstract 1372: Cediranib alone and in combination with mechanistically distinct antitumor therapies in vivo

A. Ryan, P. Elvin, Paul D. Smith, 2010 .

Clinical Cancer esearch cer Therapy : Clinical se I Safety , Pharmacokinetics , and Inhibition of Src R ivity Study of Saracatinib in Patients with Solid Tumors

I. Chirivella, J. Tabernero, P. Elvin, 2010 .

Inhibition of Src Impairs the Growth of Met-Addicted Gastric Tumors

P. Elvin, L. Trusolino, A. Bertotti, 2010, Clinical Cancer Research.

A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers.

J. Schellens, P. Elvin, G. Batist, 2015 .

Retrospective evaluation of RET biomarker status and outcome to vandetanib in four phase III randomized NSCLC trials.

R. Herbst, P. Elvin, A. Platt, 2013 .

Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer

Y. Bang, P. Elvin, S. Im, 2012, Molecular Cancer Therapeutics.